Evidence map›Paper›PMID 34461838›Full record

ArticleBMC neurology2021

Impact of social and mobility restrictions in Parkinson's disease during COVID-19 lockdown.

Raquel Luis-Martínez, Roberto Di Marco, Luca Weis, Valeria Cianci, Francesca Pistonesi, Alfonc Baba, Miryam Carecchio, Roberta Biundo, Chiara Tedesco, Stefano Masiero and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Spotlight on non-motor symptoms and Covid-19.International review of neurobiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raquel Luis-MartínezDepartment of Neurosciences, University of the Basque Country, (UPV/EHU), Leioa, Spain.
Roberto Di MarcoParkinson and Movement Disorders Unit, Department of Neurosciences, University of Padova, Via Giustiniani 5, 35138, Padua, Italy.
Luca WeisParkinson and Movement Disorders Unit, Department of Neurosciences, University of Padova, Via Giustiniani 5, 35138, Padua, Italy.
Valeria CianciParkinson and Movement Disorders Unit, Department of Neurosciences, University of Padova, Via Giustiniani 5, 35138, Padua, Italy.
Francesca PistonesiParkinson and Movement Disorders Unit, Department of Neurosciences, University of Padova, Via Giustiniani 5, 35138, Padua, Italy.
Alfonc BabaRehabilitation Unit, Azienda Ospedaliera Universitaria di Padova, Padova, Italy.
Miryam CarecchioParkinson and Movement Disorders Unit, Department of Neurosciences, University of Padova, Via Giustiniani 5, 35138, Padua, Italy.
Roberta BiundoDepartment of General Psychology, University of Padova, Padova, Italy.
Chiara TedescoParkinson and Movement Disorders Unit, Department of Neurosciences, University of Padova, Via Giustiniani 5, 35138, Padua, Italy.
Stefano MasieroPhysical Medicine and Rehabilitation School, University of Padova, Padova, Italy.
Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neurosciences, University of Padova, Via Giustiniani 5, 35138, Padua, Italy. angelo3000@yahoo.com.ORCID https://orcid.org/0000-0003-1040-2807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe consequences of strict COVID-19 mobility restrictions on motor/non-motor features in Parkinson's disease (PD) have not been systematically studied but worse mobility and quality of life have been reported. To elucidate this question, 12 mild to moderate PD patients were assessed in March 2020 before and after two months of isolation as part of a clinical study that had to be interrupted due to the pandemic and the implementation of COVID19 mobility restrictions.

methodsTwelve patients were systematically evaluated before and after the lockdown period as part of a larger cohort that previously underwent thermal water rehabilitation. Clinical outcomes were the Body Mass index, the Mini-Balance Evaluation Systems Test, the MDS-Unified Parkinson's Disease Rating Scale part III, the 6 Minute Walking Test and the New Freezing of Gait Questionnaire. Global cognition was evaluated with the Montreal Cognitive Assessment scale. The impact of COVID-19 restrictions on quality of life and functional independence was evaluated with The Parkinson's disease Quality of life (PDQ-39), the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living questionnaires (IADL) and the Parkinson's disease cognitive functional rating scales (PD-CFRS).

resultsAfter two months of isolation the Mini-BESTest score worsened (p=0.005), and four patients reported one or more falls during the lockdown. BMI increased (p=0.031) while the remaining clinical variables including quality of life did not change.

conclusionWe observed moderate worsening at Mini-BESTest, greater risk of falls and increased body weight as consequence of prolonged immobility. We believe negative effects were partially softened since patients were in contact with our multidisciplinary team during the lockdown and had previously received training to respond to the needs of this emergency isolation. These findings highligh the importnace of patient-centered interventions in PD management.

Indexed as

COVID-19Gait Disorders, NeurologicMobility LimitationParkinson DiseaseAccidental FallsActivities of Daily LivingCommunicable Disease ControlHumansMaleQuality of LifeRiskSARS-CoV-2COVID-19COVID-19 RestrictionsParkinson’s diseasePhysical activityQuarantineRehabilitationSocial isolation

Identifiers

PMID34461838
PMCPMC8404403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.